Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Kenvue on Thursday reported higher third-quarter revenue, owing to strong demand for its self-care and skincare products such as Tylenol and Neutrogena.

Kenvue reports higher Q3 revenue on self-care products strength

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced financial results for the fiscal third quarter ended October 1, 2023.

Kenvue Reports Healthy Third Quarter 2023 Results

NEW YORK , Oct. 24, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"), of the important December 8, 2023 lead plaintiff deadline. SO WHAT: If you purchased Kenvue securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Kenvue Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm - KVUE

Johnson & Johnson

Moderna

Vertex Pharmaceuticals

Instead of focusing on investing for a particular market environment, consider stocks that generally may grow over time. It's a good idea to balance your investments across stocks that offer growth and safety.

The Best Stocks to Invest $5,000 In Right Now

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP notifies investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) a securities class action lawsuit has been filed. The lawsuit seeks to recover losses on behalf of investors who acquired securities pursuant to and/or traceable to the Company's May 2023 initial public offering ("IPO"). Investors have until December 8, 2023, to apply to the Court to be appointed as lead plaintiff in the lawsuit. If you would like to review the complaint an.

KVUE Shareholder Update: Johnson Fistel Encourages Kenvue Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline

NEW YORK--(BUSINESS WIRE)---- $KVUE #classactionlawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) securities pursuant to the registration statement and related prospectus issued in connection with Kenvue's initial public offering (“IPO”). Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in th.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Kenvue Inc. (KVUE) Investors and Encourages Investors to Contact the Firm Before December 8, 2023

SAN DIEGO--(BUSINESS WIRE)---- $KVUE #IPO--Kenvue Inc. (KVUE) Made False and Misleading Statements in its Registration Statement in Support of its IPO.

KVUE Shareholders: Contact Robbins LLP About Your Rights and Remedies in the Kenvue Inc. Securities Fraud Class Action

Kenvue completed its separation from Johnson & Johnson in May, but its stock has declined over 20% since then. The company's financial results show stable margins and impressive growth, making it an attractive investment opportunity. Kenvue is significantly discounted vs. peers, suggestin

Kenvue: Very Profitable And Significantly Undervalued

Kenvue Inc., a subsidiary of Johnson & Johnson, is a major player in the consumer health industry with a diverse range of products. The company successfully completed its IPO, generating net proceeds of approximately $4.2 billion. Kenvue faces competition from industry leaders and spinoff companies, but its strong brand portfolio and global presence give it a competitive advantage.

Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 8, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company's May 2023 initial public.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

NEW YORK , Oct. 16, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"), of the important December 8, 2023 lead plaintiff deadline. SO WHAT: If you purchased Kenvue securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm - KVUE

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 8, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company's May 2023 initial public offering (the “IPO” or “Offering”). I.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Southern Company

STAG Industrial

Williams

Rising interest rates have weighed on the share prices of dividend stocks, pushing up their yields. Kenvue, Southern Company, Stag Industrial, and Williams all generate lots of cash to pay dividends and invest in growth.

4 Dividend Stocks Yielding 4% or More to Buy Without Hesitation

LOS ANGELES, CA / ACCESSWIRE / October 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "the Company") (NYSE:KVUE) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's May 2023 initial public offering ("IPO"), are encouraged to contact the firm before December 8, 2023.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses of $100,000 to Contact the Firm

Li Auto Inc.

Palantir Technologies

Rivian Automotive

Renaissance Capital LLC's passive IPO-focused ETFs loaded up on Palantir, Rivian, and Kenvue stock, and exited an investment in Li Auto in the third quarter.

An IPO Pro Buys More Palantir, Rivian, and Kenvue. It Sold Li Auto.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company's May 2023 initial public offering (the “I.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors

Corteva Inc

NextEra Energy

Sherwin-Williams

Exxon Mobil

YUM! Brands

Zimmer Biomet Hlds

While publicly traded securities that benefit from significant upside potential usually carry a higher-risk profile, with high-growth S&P 500 stocks, you can almost get the best of both worlds. To be fair, we need to set some expectations.

7 High-Growth S&P 500 Stocks to Buy Now

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company's May 2023 initial public offering (the “IPO” or “Offering”). Kenvue investors have until December 8, 2023 to file a lea.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration S.

KENVUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kenvue Inc. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) on behalf of investors concerning the Company's possible violations of federal securities laws issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"). If you suffered a loss on your Kenvue investments or would like to inquire.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Kenvue Inc. (KVUE) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) on behalf of investors concerning the Company's possible violations of federal securities laws issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"). Kenvue was previously the consumer health division of Johnson & Johnson. In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares o.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kenvue Inc. (KVUE) on Behalf of Investors

Kenvue (NYSE: KVUE) stock price crashed to a record low as the cost of living crisis continued. The shares collapsed to a low of $19.45, ~28% below the highest level this year, giving it a market cap of over $37 billion.

Kenvue stock price analysis: Short-term headwinds remain

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors

NEW YORK , Oct. 9, 2023  /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's May 2023 initial public offering ("IPO" or the "Offering"). If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2023.

EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Kenvue Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KVUE

News for Kenvue Stock (KVUE)